

# Enhancing Local Manufacturing and Supply Chain Management for Health Commodities and Supplies in Nigeria

Updates: Apr 3, 2025



# Outline



Key achievements in the last 2 weeks



Workplan tracking



Challenges and corresponding mitigation strategies



Next Steps

# Key Achievements for Reporting Period



Workstreams	Key Achievements
Administrative	<ul style="list-style-type: none"> <li>▪ Initial payment for project management and stakeholder engagement received</li> <li>▪ Initial payment for Regulatory capacity building (2) and Pooled procurement (3) submitted (Mar 12, 2025)</li> <li>▪ PVAC-HSCL documentation shared with WB</li> </ul>
Stakeholder Engagement	<ul style="list-style-type: none"> <li>▪ Executive order with malaria-related raw materials communicated to Customs for implementation</li> <li>▪ Identified Technical Oversight Partners for technical work streams:               <ul style="list-style-type: none"> <li>• RDT – Pharmaccess Foundation</li> <li>• ACT capacity – CHAI</li> <li>• API capacity – USP</li> <li>• Regulatory capacity – Empower Africa</li> <li>• Vaccines - Univercells</li> </ul> </li> </ul>
RDT Manufacturing	<ul style="list-style-type: none"> <li>▪ Discussions with Abbott Diagnostics and Roche for next generation ultra-sensitive test kits for malaria</li> </ul>
LLIN Manufacturing	<ul style="list-style-type: none"> <li>▪ MoU with Vestargard for local production in Ogun State</li> <li>▪ Discussions with Proteq on cost-effective local production with reverse integration</li> </ul>
Capacity for Regulatory Agencies	<ul style="list-style-type: none"> <li>▪ Rapid assessment ongoing by Empower to feed into capacity building areas for NADFAC and PCN</li> </ul>
Capacity for Vaccine Production and Clinical Research	<ul style="list-style-type: none"> <li>▪ Discussions with a potential partner (Univercells) for infrastructure and training. Xx persons targeted for training</li> </ul>
Project Management and M&E	<ul style="list-style-type: none"> <li>▪ M&amp;E framework being drafted</li> <li>▪ Bi-weekly meetings initiated</li> <li>▪ Terms of Reference (TORs) for the various project components have been developed - awaiting contractual clearance to proceed.</li> </ul>

# Workplan Tracking



## 8. Project Management and M&E



S/N	Activities	Time	Deliverables	Status	Comments
1	Develop a comprehensive Monitoring and Evaluation (M&E) framework	M 1	▪ Finalized M&E framework		Estimated completion Apr 18
2	Support the implementation of the M&E framework	M 1-12	▪ M&E updates		Framework being developed
3	Synthesize policy and regulatory landscape into a white paper.	M 2	▪ Finalized white-paper		Pending assessments – not yet conducted
4	Organize bi-weekly update meetings with NMEP	M 1-12	▪ Meeting notes detailing the discussions and next steps		1 <sup>st</sup> meeting Apr 3, 2025
5	Develop and submit monthly program reports by the 10th of the following month	M 1- 12	▪ Monthly project reports		To commence May 10, 2025
6	Develop quarterly financial reports	M 3, 6, 9, and 12	▪ Finalized quarterly financial reports		To commence June 2025
7	Develop end-of-project report with lessons learned for future programming	M 11-12	▪ Finalized end-of-project report		

Not started   
 Ongoing   
 Completed

# 1. Stakeholder Engagement



S/N	Activities	Time	Deliverables	Status	Comments
1	Organize engagement meetings with all key stakeholders & assign focal persons responsible for communicating and coordinating project activities	M1	<ul style="list-style-type: none"> <li>Workshop report</li> <li>Database of focal persons</li> <li>Stakeholder engagement and communication protocol document.</li> </ul>		
2	Develop and sign Memorandums of Understanding (MOUs) or formal agreements with each organization	M1	<ul style="list-style-type: none"> <li>MOUs or institutional agreements signed.</li> </ul>		Vestergaard – LLIN production Univercells – mRNA vaccine technology & clinical research US Pharmacopeia (USP)
3	Coordinate policy dialogues with key stakeholders to develop an implementation framework for priority recommendations	M2	<ul style="list-style-type: none"> <li>Priority recommendations for all project components.</li> </ul>		Pending assessments yet to be conducted
4	Organize workshops to validate findings and co-develop a strategic roadmap for vaccine, RDT, LLINs and ACT production with stakeholders.	M 3	<ul style="list-style-type: none"> <li>Stakeholder Workshop Reports</li> </ul>		Pending assessments yet to be conducted
5	Ensure all raw materials needed for producing malaria vaccines, RDTs, LLINs and ACTs are included in the presidential executive order.	M 4	<ul style="list-style-type: none"> <li>Raw materials for ACTs and other products included in executive order list</li> </ul>		Executive order communicated to customs with raw materials included (Mar 2025)

Not started   
 Ongoing   
 Completed

## 2. Capacity for RDT Manufacturing



S/N	Activities	Time	Deliverables	Status	Comments
1	Develop recommendations for critical policy and regulatory reforms required for the local manufacturing of RDTs.	M 2	<ul style="list-style-type: none"> <li>Finalized recommendations</li> </ul>		Pending assessment – not yet commenced
2	Develop a status update on capacity for RDT production through stakeholder engagement, facility visits & assessments	M 2	<ul style="list-style-type: none"> <li>Assessment report with recommendations</li> </ul>		
3	Validate findings and co-develop a strategic roadmap for malaria product (RDT) production.	M 3	<ul style="list-style-type: none"> <li>Finalized strategic roadmap</li> </ul>		
4	Finalize the selection of manufacturers for technical assistance for institutional and manufacturing capacity development	M 3	<ul style="list-style-type: none"> <li>Finalized list of RDT manufacturers</li> </ul>		
5	Provide technical support to implement the strategic roadmap for local manufacturers of RDTs	M 4-11	<ul style="list-style-type: none"> <li>Reports on technical assistance provided</li> </ul>		

Not started   
 Ongoing   
 Completed

### 3. Capacity for ACT and API Manufacturing



S/N	Activities	Time	Deliverables	Status	Comments
1	Develop recommendations for critical policy and regulatory reforms required for the local manufacturing of malaria ACTs and APIs	M 2	<ul style="list-style-type: none"> <li>Finalized recommendations</li> </ul>		Pending assessment – not yet commenced
2	Develop a status update on the capacity for malaria ACTs and APIs production through stakeholder engagement, facility visits, and assessment	M 2	<ul style="list-style-type: none"> <li>Assessment report with recommendations</li> </ul>		
3	Explore local sourcing of inputs for producing malaria ACTs and APIs from other local sectors (e.g., petrochemical industry)	M 3	<ul style="list-style-type: none"> <li>List of priority local available inputs and potential engagement framework.</li> </ul>		
4	Validate findings and co-develop a strategic roadmap for malaria ACTs and APIs production.	M 3	<ul style="list-style-type: none"> <li>Finalized strategic roadmap</li> </ul>		
5	Finalize the selection of manufacturers for technical assistance for institutional and manufacturing capacity development	M 3	<ul style="list-style-type: none"> <li>Finalized list of RDT manufacturers</li> </ul>		
6	Provide technical support to implement the strategic roadmap for local manufacturers of malaria ACTs and APIs.	M 4-11	<ul style="list-style-type: none"> <li>Reports on technical assistance provided</li> </ul>		

Not started   
 Ongoing   
 Completed

## 4. Capacity for LLIN Manufacturing



S/N	Activities	Time	Deliverables	Status	Comments
1	Develop recommendations for critical policy and regulatory reforms required for the local manufacturing of LLINs	M 2	<ul style="list-style-type: none"> <li>Finalized recommendations</li> </ul>		Pending assessment – not yet commenced
2	Develop a status update on the capacity for LLINs production through stakeholder engagement, facility visits, and assessment	M 2	<ul style="list-style-type: none"> <li>Assessment report with recommendations</li> </ul>		
3	Validate findings and co-develop a strategic roadmap for LLINs production.	M 3	<ul style="list-style-type: none"> <li>Finalized strategic roadmap</li> </ul>		
4	Finalize the selection of manufacturers for technical assistance for institutional and manufacturing capacity development	M 3	<ul style="list-style-type: none"> <li>Finalized list of LLINs manufacturers</li> </ul>		
5	Provide technical support to implement the strategic roadmap for local manufacturers of LLINs	M 4-11	<ul style="list-style-type: none"> <li>Reports on technical assistance provided</li> </ul>		

Not started   
 Ongoing   
 Completed

## 5. Capacity for Regulatory Agencies



S/N	Activities	Time	Deliverables	Status	Comments
1	Identify respective regulatory agencies' (e.g. NAFDAC, PCN and others TBD from mapping) support needs	M 3	<ul style="list-style-type: none"> <li>Finalized report</li> </ul>		Rapid assessment of capacity assessment is ongoing to inform in-depth-assessment
2	Co-develop (with regulatory agencies) a short and mid-term capacity development plan	M 3	<ul style="list-style-type: none"> <li>Finalized costed capacity development plan</li> </ul>		
3	Regulatory harmonization for manufacturing standards.	M 4	<ul style="list-style-type: none"> <li>A comprehensive framework or set of guidelines</li> </ul>		
4	Enhance market surveillance and quality control.	M 5	<ul style="list-style-type: none"> <li>Market surveillance and quality control framework</li> </ul>		
5	Facilitate the establishment of a NAFDAC-led quality assurance task force.	M 3	<ul style="list-style-type: none"> <li>Established NAFDAC-led QA task force</li> </ul>		
6	Provide technical assistance to NAFDAC	M 4-11	<ul style="list-style-type: none"> <li>Reports on technical assistance provided</li> </ul>		

Not started   
 Ongoing   
 Completed

## 6. Capacity for Pooled Procurement



S/N	Activities	Time	Deliverables	Status	Comments
1	Conduct a comprehensive assessment of the current capacities for pooled procurement at state and national levels	M 4	<ul style="list-style-type: none"> <li>Finalized assessment report</li> </ul>		
2	Co-develop a phased intervention plan with stakeholders	M 4	<ul style="list-style-type: none"> <li>Finalized costed capacity development plan</li> </ul>		
3	Establish a committee for pooled procurement of malaria commodities	M 4	<ul style="list-style-type: none"> <li>State level pooled procurement committees</li> </ul>		
4	Provide technical support for pooled procurement at state and national levels	M 5	<ul style="list-style-type: none"> <li>Centralized procurement guidelines.</li> <li>Report on technical assistance provided</li> </ul>		
5	Strengthen inventory management and visibility	M 3	<ul style="list-style-type: none"> <li>Implemented digital tools for inventory management</li> </ul>		

Not started
 Ongoing
 Completed

## 6. Capacity for Vaccine Production and Clinical Research



S/N	Activities	Time	Deliverables	Status	Comments
1	Develop a status update on in-country capacity for vaccine production by different vaccine types – LAV, mRNA, etc., including malaria vaccines.	M 4	<ul style="list-style-type: none"> <li>Finalized status update report</li> </ul>		
2	Develop recommendations for critical policy and regulatory reforms required for the local manufacturing of vaccines.	M 4	<ul style="list-style-type: none"> <li>Finalized recommendations for local manufacturing of vaccines</li> </ul>		
3	Identify collaboration opportunities with regional initiatives such as RVSC, etc. (emphasizing malaria vaccines) and key participation steps.	M 4	<ul style="list-style-type: none"> <li></li> </ul>		
4	Collaborate with stakeholders to identify potential clinical trial locations/sites that can participate in clinical research into new therapeutics and other interventions.	M 5	<ul style="list-style-type: none"> <li>Database of local site for vaccine trials</li> </ul>		
5	Establish partnerships to expand innovative clinical research to local sites and strengthen the capacity and quality of clinical research.	M 3	<ul style="list-style-type: none"> <li>Map of potential partnerships to strengthen in-country capacity for vaccine and other research</li> </ul>		

Not started
 Ongoing
 Completed

## M&E Framework

Develop the draft M&E framework or the project.

## Stakeholder Engagement

Continue stakeholder engagement (including representatives from NAFDAC, NPSCMP, Association of Local Manufacturers, etc.).

## TORs


Publish TORs for consultants and partners

## TOG

Set up a Technical Oversight Group (TOG).

## Consultants Selection

Finalize the selection of consultants for the different components of the project.



Thank You!

